Table 1.
Pro-inflammatory signaling pathway inhibitors for COPD.
| S. no. | Inhibitor/drug | Mechanism/effect | Clinical progress | References |
|---|---|---|---|---|
| 1 | RV568 | P38MAPK pathway inhibitor | No effect (NCT01475292) (NCT01661244) |
[135] |
|
| ||||
| 2 | Nemiralisib (GSK2269557) |
PI3K inhibitor | 28 Days treatment (NCT02294734) 84 Days treatment (NCT02522299) |
[136] |
|
| ||||
| 3 | RV1729 | PI3K inhibitor | Phase I Trial, limited efficacy (NCT02140346) | [136, 137] |
|
| ||||
| 4 | VIP (vasoactive intestinal peptide) | Increases cAMP, adenylate cyclase, and phospholipase C | 3 Months inhaled treatment (NCT00464932) |
[138, 139] |
|
| ||||
| 5 | Adenosine A2A receptor (UK-432097) |
cAMP enhancer | No effect (NCT00430300) |
[140, 141] |
|
| ||||
| 6 | AZD1981 | Prostaglandin D2 receptor inhibitor | No effect (NCT00690482) |
[142] |
|
| ||||
| 7 | Bimosiamose | Selectins inhibitor | 28 Days inhalation treatment (NCT01108913) |
[143] |